期刊
LANCET INFECTIOUS DISEASES
卷 13, 期 9, 页码 785-796出版社
ELSEVIER SCI LTD
DOI: 10.1016/S1473-3099(13)70190-7
关键词
-
资金
- Sage and Steris
- Merck
- grant Narodowy Program Ochrony Antybiotykow (NPOA) from the Polish Ministry of Health
- grant SPUB MIKROBANK from the Polish Ministry of Science and Higher Education
- Pfizer
- Novartis
- AstraZeneca
- Astellas
- Merck Sharp Dohme
- Pfizer SA
- Janssen-Cilag SA
- Merck Colombia
- AstraZeneca Colombia SA
- bioMerieux Colombia SAS
- Colciencias
Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile beta-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据